Bree R Eaton1, Hyun S Kim2, Eduard Schreibmann3, David M Schuster4, James R Galt5, Bruce Barron4, Sungjin Kim6, Yuan Liu6, Jerome Landry3, Tim Fox3. 1. Department of Radiation Oncology, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322; Winship Cancer Institute, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322. Electronic address: brupper@emory.edu. 2. Department of Radiology and Imaging Sciences, Divisions of Interventional Radiology and Image Guided Medicine, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322; Winship Cancer Institute, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322. 3. Department of Radiation Oncology, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322; Winship Cancer Institute, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322. 4. Divisions of Nuclear Medicine and Molecular Imaging, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322; Winship Cancer Institute, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322. 5. Divisions of Nuclear Medicine and Molecular Imaging, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322. 6. Departments of Biostatistics and Bioinformatics, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322; Winship Cancer Institute, Emory University, 1365 Clifton Road NE, Suite CT 104, Atlanta, GA 30322.
Abstract
PURPOSE: To assess a new method for generating patient-specific volumetric dose calculations and analyze the relationship between tumor dose and positron emission tomography (PET) response after radioembolization of hepatic melanoma metastases. METHODS AND MATERIALS: Yttrium-90 ((90)Y) bremsstrahlung single photon emission computed tomography (SPECT)/computed tomography (CT) acquired after (90)Y radioembolization was convolved with published (90)Y Monte Carlo estimated dose deposition kernels to create a three-dimensional dose distribution. Dose-volume histograms were calculated for tumor volumes manually defined from magnetic resonance imaging or PET/CT imaging. Tumor response was assessed by absolute reduction in maximum standardized uptake value (SUV(max)) and total lesion glycolysis (TLG). RESULTS: Seven patients with 30 tumors treated with (90)Y for hepatic metastatic melanoma with available (90)Y SPECT/CT and PET/CT before and after treatment were identified for analysis. The median (range) for minimum, mean, and maximum dose per tumor volume was 16.9 Gy (5.7-43.5 Gy), 28.6 Gy (13.8-65.6 Gy) and 36.6 Gy (20-124 Gy), respectively. Response was assessed by fluorodeoxyglucose PET/CT at a median time after treatment of 2.8 months (range, 1.2-7.9 months). Mean tumor dose (P = .03) and the percentage of tumor volume receiving ≥ 50 Gy (P < .01) significantly predicted for decrease in tumor SUV(max), whereas maximum tumor dose predicted for decrease in tumor TLG (P < .01). CONCLUSIONS: Volumetric dose calculations showed a statistically significant association with metabolic tumor response. The significant dose-response relationship points to the clinical utility of patient-specific absorbed dose calculations for radionuclide therapy.
PURPOSE: To assess a new method for generating patient-specific volumetric dose calculations and analyze the relationship between tumor dose and positron emission tomography (PET) response after radioembolization of hepatic melanoma metastases. METHODS AND MATERIALS: Yttrium-90 ((90)Y) bremsstrahlung single photon emission computed tomography (SPECT)/computed tomography (CT) acquired after (90)Y radioembolization was convolved with published (90)Y Monte Carlo estimated dose deposition kernels to create a three-dimensional dose distribution. Dose-volume histograms were calculated for tumor volumes manually defined from magnetic resonance imaging or PET/CT imaging. Tumor response was assessed by absolute reduction in maximum standardized uptake value (SUV(max)) and total lesion glycolysis (TLG). RESULTS: Seven patients with 30 tumors treated with (90)Y for hepatic metastatic melanoma with available (90)Y SPECT/CT and PET/CT before and after treatment were identified for analysis. The median (range) for minimum, mean, and maximum dose per tumor volume was 16.9 Gy (5.7-43.5 Gy), 28.6 Gy (13.8-65.6 Gy) and 36.6 Gy (20-124 Gy), respectively. Response was assessed by fluorodeoxyglucose PET/CT at a median time after treatment of 2.8 months (range, 1.2-7.9 months). Mean tumor dose (P = .03) and the percentage of tumor volume receiving ≥ 50 Gy (P < .01) significantly predicted for decrease in tumor SUV(max), whereas maximum tumor dose predicted for decrease in tumorTLG (P < .01). CONCLUSIONS: Volumetric dose calculations showed a statistically significant association with metabolic tumor response. The significant dose-response relationship points to the clinical utility of patient-specific absorbed dose calculations for radionuclide therapy.
Authors: Arthur J A T Braat; Julia E Huijbregts; I Quintus Molenaar; Inne H M Borel Rinkes; Maurice A A J van den Bosch; Marnix G E H Lam Journal: Front Oncol Date: 2014-07-30 Impact factor: 6.244
Authors: Jill Wevrett; Andrew Fenwick; James Scuffham; Lena Johansson; Jonathan Gear; Susanne Schlögl; Marcel Segbers; Katarina Sjögreen-Gleisner; Pavel Solný; Michael Lassmann; Jill Tipping; Andrew Nisbet Journal: EJNMMI Phys Date: 2018-08-02
Authors: S C Ebbers; B Kunnen; B J van Nierop; J L M Bemelmans; G C Krijger; M G E H Lam; A J A T Braat Journal: Cardiovasc Intervent Radiol Date: 2020-05-20 Impact factor: 2.740
Authors: Nichole M Maughan; Mootaz Eldib; David Faul; Maurizio Conti; Mattijs Elschot; Karin Knešaurek; Francesca Leek; David Townsend; Frank P DiFilippo; Kimberly Jackson; Stephan G Nekolla; Mathias Lukas; Michael Tapner; Parag J Parikh; Richard Laforest Journal: EJNMMI Phys Date: 2018-04-04
Authors: Remco Bastiaannet; S Cheenu Kappadath; Britt Kunnen; Arthur J A T Braat; Marnix G E H Lam; Hugo W A M de Jong Journal: EJNMMI Phys Date: 2018-11-02
Authors: Peter S Potrebko; Ravi Shridhar; Matthew C Biagioli; William F Sensakovic; George Andl; Jan Poleszczuk; Timothy H Fox Journal: J Appl Clin Med Phys Date: 2018-07-01 Impact factor: 2.102